Achaogen is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE. Achaogen is also developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens. Achaogen's research and development pipeline includes additional gram-negative programs such as inhibitors of LpxC, an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program.

Type
Public
HQ
South San Francisco, US
Founded
2004
Size (employees)
194 (est)+84%
Achaogen was founded in 2004 and is headquartered in South San Francisco, US
Report incorrect company information

Achaogen Office Locations

Achaogen has an office in South San Francisco
South San Francisco, US (HQ)
371 7000 Shoreline Ct
Show all (1)
Report incorrect company information

Achaogen Financials and Metrics

Achaogen Financials

Achaogen's revenue was reported to be $11.18 m in FY, 2017
USD

Revenue (FY, 2017)

11.2 m

Net income (FY, 2017)

(125.6 m)

EBIT (FY, 2017)

(126.3 m)

Market capitalization (25-Apr-2018)

518.6 m

Cash (31-Dec-2017)

145.2 m
Achaogen's current market capitalization is $518.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

20 m26.1 m41.8 m11.2 m

Revenue growth, %

31%60%

General and administrative expense

9.6 m12.4 m17.1 m41.9 m

R&D expense

30.1 m40.2 m74 m95.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

6 m5.2 m4.5 m4.9 m12 m4.5 m5.8 m9.1 m16 m7.5 m1.3 m

General and administrative expense

2.6 m2.3 m2.2 m3.2 m2.9 m3 m3.8 m4 m4.5 m6.8 m8.9 m

R&D expense

6.6 m6.2 m10.7 m7.9 m10.1 m10 m13.9 m21.7 m20.5 m18.6 m22.2 m

Operating expense total

9.2 m8.5 m12.9 m11.1 m13 m13 m17.7 m25.7 m25 m25.3 m31.1 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

18.9 m20.3 m119 m145.2 m

Accounts Receivable

301 k

Inventories

210.1 m

Current Assets

69.4 m65.5 m160.3 m178.4 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

84.9 m74.5 m46.9 m22.9 m39.5 m35.1 m19.4 m54.6 m41.8 m37.6 m144 m

Current Assets

91.1 m80.4 m76.6 m66.7 m66.6 m76.1 m57.9 m81.3 m79.4 m147.1 m248.2 m

PP&E

662 k615 k662 k648 k902 k836 k1.1 m995 k1 m8.4 m11.4 m

Total Assets

92 m81.2 m77.4 m67.5 m67.7 m77.4 m59.2 m82.3 m80.7 m155.8 m263.2 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(20.2 m)(27.1 m)(71.2 m)(125.6 m)

Depreciation and Amortization

358 k426 k441 k1.3 m

Accounts Payable

5.7 m

Cash From Operating Activities

8.1 m1.4 m(46.9 m)(95.3 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.3 m)(6.2 m)(886 k)(8.8 m)(12.2 m)(18.3 m)(11 m)(33.3 m)

Accounts Payable

2.6 m6.2 m3.9 m4 m5.3 m6.6 m6.1 m7.6 m11.6 m
USDY, 2017

Revenue/Employee

92.6 k

Financial Leverage

1.6 x
Show all financial metrics
Report incorrect company information

Achaogen News and Updates

Aminoglycosides Market is Set to Experience Revolutionary Growth by 2025

North America dominates the global aminoglycoside market in terms of value due to increase in bacterial infections and introduction of novel, key players for production of aminoglycoside. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information